Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune
Former Generate Biomedicines, Amgen and Novartis senior leader Mike Nohaile joins Prellis as CEOSAN FRANCISCO--(BUSINESS WIRE)--Prellis Biologics, Inc (Prellis Bio), a biotherapeutics company, today appointed Michael Nohaile, PhD as its new CEO and announced it has raised a $35 million Series C funding round, co-led...
Source: pharmiweb.com